Equities
Health CareMedical Equipment and Services
  • Price (SEK)42.18
  • Today's Change0.36 / 0.86%
  • Shares traded91.30k
  • 1 Year change-12.60%
  • Beta0.4477
Data delayed at least 15 minutes, as of Jul 23 2024 11:44 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Arjo AB (publ) is a Sweden-based supplier of products, services and solutions for people with reduced mobility and age-related health challenges. The Company’s offering includes products and solutions within the product segments Patient handling, Hygiene, Disinfection, Therapeutic surfaces, Venous Thromboembolism (VTE) prevention and Diagnostics. Additionally, the Company is offering its customers complementing services. The products comprise ceiling lifts, standing and raising aids, slings, floor lifters, among others. Arjo AB (publ) operates in more than 60 countries, which the Company divides into three geographical areas: North America, Western Europe and Rest of the World.

  • Revenue in SEK (TTM)11.23bn
  • Net income in SEK536.00m
  • Incorporated2016
  • Employees6.94k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sedana Medical AB (publ)164.91m-22.83m2.62bn83.00--2.6538,566.1115.90-0.2299-0.22991.669.950.15641.248.102,087,443.00-2.17-5.77-2.28-6.0870.5064.06-13.85-36.137.38--0.0043--25.2321.5918.90--42.12--
Detection Technology Oyj-1.17tn-1.17tn2.73bn478.00--3.21----------4.97----------9.34--11.96--47.44--8.223.13--0.08153.455.292.027.55-18.03-14.88-9.55
Medistim ASA520.22m100.48m3.05bn152.0030.257.2224.525.855.605.6029.0123.481.030.77656.153,492,704.0019.9522.9324.0728.5279.0278.2519.3120.642.99--0.020675.257.0010.06-8.9112.720.03314.87
BICO Group AB2.26bn-1.61bn3.18bn837.00--1.07--1.41-22.34-26.3931.7342.970.33982.334.142,555,996.00-24.19---27.59--50.48---71.20--1.95-13.810.3933--6.09---1,889.33------
RaySearch Laboratories AB (publ)1.05bn100.71m3.71bn398.0047.446.159.493.542.942.9430.6422.650.53135.652.972,697,136.005.101.297.801.8889.9290.579.602.551.1947.170.403669.0021.1610.26243.060.7648-1.31--
Surgical Science Sweden AB842.02m207.95m6.60bn265.0031.721.4424.917.844.084.0816.5189.920.17491.686.123,238,531.004.324.494.594.7868.5970.0624.7023.753.53--0.000.0010.0168.1424.47--38.57--
CellaVision AB708.28m141.22m6.65bn223.0047.128.7736.589.405.925.9229.6931.810.7571.688.453,106,469.0015.0915.3017.3418.2467.5269.0319.9419.982.2166.290.0688110.185.9413.1710.128.0030.458.45
Revenio Group Oyj1.13bn221.90m9.18bn216.0040.897.8434.248.130.72050.72053.663.760.70695.507.60447,574.1013.9014.3316.7717.9051.0150.7319.6621.131.7928.490.152155.81-0.412525.80-12.1518.7217.676.30
ChemoMetec A/S628.18m224.96m10.57bn171.0047.0113.5541.6716.838.268.2623.0728.660.69820.80646.012,448,421.0025.0030.4329.6938.9978.8579.4435.8134.173.37--0.011846.903.7431.5812.0457.8819.91--
Arjo AB (publ)11.23bn536.00m10.97bn6.94k21.931.487.090.97721.971.9741.2129.200.69574.406.511,651,221.003.313.554.515.5543.6844.014.765.410.66574.010.412343.0110.035.976.9010.15-8.8910.35
Biotage AB2.08bn250.00m15.21bn667.0060.894.0135.457.333.123.1225.9347.360.42171.706.573,080,119.005.0810.745.8712.7762.7261.3412.0415.771.148.710.062840.1118.9015.37-8.217.9714.051.30
Xvivo Perfusion AB698.73m120.74m16.95bn152.00136.328.3789.4524.253.953.9522.6964.280.34411.224.484,367,031.005.951.246.451.3374.1673.1417.284.763.27--0.01330.0043.8826.04398.2948.5721.35--
Embla Medical hf8.63bn610.60m19.51bn4.00k31.872.4816.822.260.91490.914912.9111.740.55822.206.601,378,933.003.964.064.684.7661.4162.477.096.911.075.810.43253.999.335.0937.34-6.056.50--
Data as of Jul 23 2024. Currency figures normalised to Arjo AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

29.61%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 30 Apr 202426.03m10.24%
The Vanguard Group, Inc.as of 30 Apr 20248.27m3.25%
Svolder AB (Investment Management)as of 30 Apr 20247.60m2.99%
F�rsta AP-fondenas of 30 Apr 20246.50m2.56%
Dimensional Fund Advisors LPas of 30 Apr 20246.28m2.47%
Norges Bank Investment Managementas of 31 Dec 20235.54m2.18%
Handelsbanken Fonder ABas of 30 Jun 20243.97m1.56%
BlackRock Fund Advisorsas of 30 Apr 20243.89m1.53%
SEB Investment Management ABas of 30 Apr 20243.83m1.51%
Oddo BHF Asset Management SASas of 28 Jun 20243.34m1.32%
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.